Improving Preclinical Neuroscience Study Design with AlzPED Data
Potential neurodegenerative disease therapies may show efficacy in preclinical research, but too often cannot be replicated or fail to translate from in vivo platforms to clinical results. This makes drug development slower, more expensive, and financially risky.
Improving the design of efficacy studies could solve this problem. We need a central resource for sharing preclinical efficacy data and best practices in this emerging field.
The Alzheimer’s Disease Preclinical Efficacy Database (AlzPED)
The Alzheimer’s Disease Preclinical Efficacy Database (AlzPED) is a web-based knowledge portal for housing, sharing, and mining preclinical efficacy data. Each study is curated by two experts for potential conflicts of interest, AD animal models, targets, outcomes, and – most importantly – the rigor of the study.
In this webinar, we join Dr. Lorenzo Refolo, Director for Alzheimer’s Disease Drug Discovery and Development at the National Institute on Aging (NIA), to learn how AlzPED can promote the reproducibility and translatability of neuroscience research.
Watch this webinar to:
- Identify elements of rigorous study design and requirements for transparent reporting.
- Discuss best practices for rigorous preclinical testing of candidate therapeutics for neurodegenerative disease.
- Learn how to mine AlzPED for data on preclinical efficacy studies of your disease of interest.
Director for Alzheimer’s Disease Drug Discovery and Development | NIA
Dr. Refolo is the Director for Alzheimer’s Disease Drug Discovery and Development at the NIA. He received his PhD in Molecular Genetics from the Rutgers University School of Medicine, with postdoctoral training at the Laboratory of Neurobiology at Rockefeller University and the Department of Psychiatry at Mount Sinai School of Medicine. He joined the NIH as a Program Director at the National Institute of Neurological Disorders and Stroke, managing a portfolio of basic, clinical, and translational research that was focused on neurodegenerative diseases. He has been at the NIA since 2010, developing and managing a diverse portfolio of translational research programs aimed at developing new therapies for Alzheimer’s disease.